Group 1: Financial Performance - The company achieved a revenue of 13.68 billion yuan in the first three quarters of 2025, representing a year-on-year growth of 8.17% [2] - In Q3 2025, the revenue reached 2.83 billion yuan, marking an increase of 11.72% [2] - The net profit attributable to shareholders for the first three quarters was 4,273 million yuan, with a net profit of 1,735 million yuan in Q3 [2] Group 2: Strategic Planning - The Boston R&D base in the U.S. commenced operations in September 2025, enhancing local service capabilities [3] - The company aims for a revenue growth rate exceeding 15% and to achieve profitability by 2025, with strategic effects expected to manifest in 2026 [3] - By 2027, the company plans to enter a phase of significant growth [3] Group 3: Business Development - The company is expanding its integrated service capabilities and focusing on new modalities, including XDC, small nucleic acids, AOC, and POC [3] - Domestic business growth is driven by the rebuilding of the BD team and strong research capabilities, leading to increased order recognition [4] - The company is actively pursuing investment in industry funds to identify promising biopharmaceutical projects [5] Group 4: Market Trends and Orders - The order scale has shown steady growth, with significant recovery in domestic business and a rebound in overseas markets [5] - The company has completed team restructuring to enhance client maintenance and new customer acquisition [5] - The market order prices have started to rebound, and the company is enhancing its R&D capabilities to strengthen its competitive edge [5]

Core Insights - RuiZhi Pharmaceutical is a leading pharmaceutical research and production outsourcing service provider in China, established on January 26, 2000, and listed on the Shenzhen Stock Exchange on December 22, 2010 [1] Financial Performance - For Q3 2025, RuiZhi Pharmaceutical reported revenue of 817 million yuan, ranking 13th among 29 companies in the industry. The top company, WuXi AppTec, had revenue of 32.857 billion yuan, while the industry average was 2.547 billion yuan [2] - The main business revenue from pharmaceutical research and production outsourcing services was 529 million yuan, accounting for 99.06% of total revenue. Other revenues included 2.7823 million yuan from prebiotic products (0.52%), 1.846 million yuan from rental income (0.35%), and 397,300 yuan from other sources (0.07%) [2] - The net profit for the same period was 7.1621 million yuan, ranking 23rd in the industry. The leading company, WuXi AppTec, reported a net profit of 12.206 billion yuan, with the industry average at 585 million yuan [2] Financial Ratios - As of Q3 2025, RuiZhi Pharmaceutical's debt-to-asset ratio was 35.77%, higher than the previous year's 35.56% and above the industry average of 22.79% [3] - The gross profit margin for the period was 27.55%, an increase from 19.22% in the previous year, but still below the industry average of 37.70% [3] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 4.70% to 42,600, while the average number of circulating A-shares held per shareholder increased by 4.94% to 11,200 [5] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited ranked as the fourth largest, holding 24.3258 million shares, a decrease of 6,100 shares from the previous period [5] Leadership Compensation - The chairman, Hu Ruilian, received a salary of 1.2011 million yuan in 2024. He holds multiple positions, including CEO and director of RuiZhi Pharmaceutical [4]

Core Viewpoint - Ruizhi Pharmaceutical (300149) announced that neither the company nor its controlling subsidiaries have any overdue external guarantees, nor are there any amounts related to guarantees involved in litigation or any amounts to be borne due to guarantee-related judgments [1] Group 1 - The company confirmed the absence of overdue external guarantees [1] - There are no amounts related to guarantees that are involved in litigation [1] - The company has not been ordered to bear any amounts due to guarantee-related judgments [1]

睿智医药科技股份有限公司 信息披露暂缓与豁免管理制度 第一章 总则 第一条 为规范睿智医药科技股份有限公司（以下简称"公司"）的信息披露 暂缓与豁免行为，督促公司及相关信息披露义务人依法合规履行信息披露义务， 保护投资者的合法权益，根据《中华人民共和国公司法》《中华人民共和国证券 法》《上市公司信息披露管理办法》《深圳证券交易所上市公司自律监管指引第 2号——创业板上市公司规范运作》《上市公司信息披露暂缓与豁免管理规定》 等有关法律、行政法规、部门规章和规范性文件及《睿智医药科技股份有限公司 章程》（以下简称《公司章程》）的有关规定，结合公司实际情况，制定本制度。 第二条 公司和其他信息披露义务人暂缓、豁免披露临时报告，在定期报告、 临时报告中豁免披露中国证券监督管理委员会（以下简称"中国证监会"）和深 圳证券交易所（以下简称"深交所"）规定或者要求披露的内容，适用本制度。 第三条 公司和其他信息披露义务人应自行审慎判断应当披露的信息是否 适用相关规定中的暂缓、豁免情形，并采取有效措施防止暂缓或者豁免披露的信 息泄露，接受中国证监会、深交所对有关信息披露暂缓、豁免事项的事后监管。 第二章 信息披露暂缓与豁免的 ...

证券代码：300149 证券简称：睿智医药 公告编号：2025-72 睿智医药科技股份有限公司 关于为子公司增加担保额度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 睿智医药科技股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日召开的 第六届董事会第十三次会议审议通过了《关于为子公司增加担保额度的议案》， 根据相关法律法规及《公司章程》的规定，本次增加担保额度事项尚需提交公司 股东会审议通过。现将相关事宜公告如下： 一、担保情况概述 （一）已审批的担保额度情况 公司分别于 2025 年 4 月 27 日、2025 年 5 月 30 日召开第六届董事会第六次 会议、第六届监事会第六次会议和 2024 年年度股东会，审议通过了《关于向银行 等金融机构申请综合授信额度并提供担保的议案》，同意 2025 年度公司为子公司 （含子公司之间）提供担保额度合计为不超过人民币 18,000 万元。具体内容详见 公司于 2025 年 4 月 29 日在巨潮资讯网（www.cninfo.com.cn）上披露的《关于向 银行等金融机构申请综合授信额度并提 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 睿智医药科技股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日召开的 第六届董事会第十三次会议审议通过了《关于关联方对全资子公司增资及对外投 资设立合资公司暨关联交易的议案》，现将相关事宜公告如下： 一、关联交易概述 为满足公司全资子公司广东享百年健康科技有限公司（以下简称"享百年健 康科技"）经营发展需求，增强其资本实力，拟增资扩股引入公司关联方江门市 安欣投资有限公司（以下简称"安欣投资"）对享百年健康科技进行增资，安欣 投资拟以货币方式向享百年健康科技增资人民币 4,803,921.57 元。公司将放弃本 次享百年健康科技增资的优先认缴出资权。本次增资完成后，享百年健康科技的 注册资本将由人民币 5,000,000 元增至人民币 9,803,921.57 元。公司对享百年健康 科技的出资额不变，持股比例由 100%下降至 51%，享百年健康科技由公司全资 子公司变更为控股子公司，不会导致公司合并报表范围变更。 同时，享百年健康科技拟与安欣投资共同投资设立广州享百年生物技术有限 公司（暂定名 ...

证券代码：300149 证券简称：睿智医药 公告编号：2025-70 睿智医药科技股份有限公司 关于续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 本次续聘会计师事务所事项符合财政部、国务院国资委、证监会印发的《国 有企业、上市公司选聘会计师事务所管理办法》（财会【2023】4 号）的规定。 睿智医药科技股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日召开 第六届董事会第十三次会议，审议通过了《关于续聘会计师事务所的议案》，同 意续聘立信会计师事务所（特殊普通合伙）（以下简称"立信"）为公司 2025 年 度的财务审计及内部控制审计机构，聘任期为一年。本事项尚需提交公司股东会 审议通过。现将相关事项公告如下： 一、拟续聘会计师事务所的基本情况 （一）机构信息 1、基本信息 立信会计师事务所（特殊普通合伙）由我国会计泰斗潘序伦博士于 1927 年 在上海创建，1986 年复办，2010 年成为全国首家完成改制的特殊普通合伙制会 计师事务所，注册地址为上海市，首席合伙人为朱建弟先生。立信是国际会计网 络 BD ...

1、股东会届次：2025 年第二次临时股东会 证券代码：300149 证券简称：睿智医药 公告编号：2025-73 睿智医药科技股份有限公司 关于召开 2025 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、召开会议的基本情况 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创业板股票 上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》等 法律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 11 月 17 日 14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 17 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投票的具 体时间为 2025 年 11 月 17 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2025 ...

证券代码：300149 证券简称：睿智医药 公告编号：2025-69 睿智医药科技股份有限公司 第六届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 睿智医药科技股份有限公司（以下简称"公司"）第六届董事会第十三次会 议于 2025 年 10 月 29 日以现场结合通讯方式召开。会议通知以书面、电话或 电子邮件方式送达。会议应到董事 6 人，实到 6 人。会议由公司董事长WOO SWEE LIAN先生主持，公司高级管理人员列席了会议。本次会议召集与召开 符合有关法律、行政法规、部门规章和《公司章程》的有关规定。经与会董事 认真审议，形成决议如下： 1、审议通过了《关于2025年三季度报告的议案》 公司2025年三季度报告真实反映了公司的经营情况。 本议案已经公司董事会审计委员会审议通过。具体内容详见公司同日在 巨潮资讯网（www.cninfo.com.cn）上披露的相关公告。 本议案以6票同意，0票反对，0票弃权获得通过。 2、审议通过了《关于续聘会计师事务所的议案》 董事会同意续聘立信会计师事务所（特殊普通合伙）为公司2025年度 ...

Financial Performance - The company's revenue for Q3 2025 was ¥283,050,158.28, representing an increase of 11.72% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥18,290,817.17, a significant decrease of 1,575.68% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥21,141,831.69, down 322.61% from the previous year[5]. - The company reported a net cash flow from operating activities of ¥120,235,170.12, an increase of 6.83% year-to-date[5]. - The company implemented an equity incentive plan, which impacted the net profit figures, showing a net profit of ¥42,728,200 for the first three quarters of 2025, a year-on-year increase of 169.29%[5]. - The net profit attributable to shareholders of the listed company for the first three quarters of 2025 was CNY 42.73 million, representing a year-on-year increase of 169.29%[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 21.29 million, showing a year-on-year growth of 130.83%[19]. - Net profit for the current period was ¥7,162,056.65, a significant recovery from a net loss of ¥61,782,349.49 in the previous period[25]. - The company reported a total comprehensive income of ¥4,882,472.92, compared to a loss of ¥71,216,290.10 in the prior period[26]. - Basic and diluted earnings per share improved to ¥0.0142 from a loss of ¥0.1238 in the previous period[26]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,989,453,565.68, a decrease of 0.32% compared to the end of the previous year[5]. - The total current assets as of September 30, 2025, amounted to CNY 697.46 million, an increase from CNY 644.07 million at the beginning of the period[20]. - The total assets of the company were CNY 1.99 billion, slightly down from CNY 1.996 billion at the beginning of the period[21]. - The total liabilities of the company as of September 30, 2025, were CNY 332.73 million, compared to CNY 346.70 million at the beginning of the period[21]. - The total liabilities decreased to ¥711,624,278.12 from ¥757,745,151.71, indicating a reduction of approximately 6.1%[22]. - Total equity attributable to shareholders of the parent company increased to ¥1,253,557,011.18 from ¥1,213,861,296.55, reflecting a growth of 3.3%[22]. - Deferred income decreased to ¥24,889,143.90 from ¥28,360,653.06, a decline of 12.3%[22]. Cash Flow - Cash flow from operating activities generated ¥120,235,170.12, an increase from ¥112,545,118.85 in the previous period[27]. - The net cash flow from investment activities was -$54.49 million, a decrease from -$58.43 million in the previous period[28]. - Total cash inflow from financing activities was $40.30 million, compared to $28.45 million in the prior period[28]. - The net cash flow from financing activities was -$65.05 million, an improvement from -$81.21 million year-over-year[28]. - The ending balance of cash and cash equivalents was $362.39 million, down from $313.53 million in the previous year[28]. - The company reported a total cash outflow from investment activities of $133.89 million, significantly higher than $64.23 million last year[28]. - Cash received from borrowings amounted to $5.00 million, a decrease from $28.45 million in the previous period[28]. - The cash outflow for repayment of debts was $14.26 million, compared to $62.13 million in the previous year[28]. Expenses - The company’s sales expenses increased by 50.37% to ¥42,602,703.70 due to higher marketing and advertising costs[11]. - The investment income rose by 89.47% to ¥13,835,351.40, primarily from the sale of equity in a subsidiary[11]. - The company recognized share-based payment expenses of CNY 35.64 million for the equity incentive plan during the first three quarters of 2025[19]. - The company reported an increase in research and development expenses to ¥41,853,143.70 from ¥45,275,069.93, a decrease of 7.5%[24]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 42,558[12]. - The company granted 44.56 million restricted stock to 123 incentive objects at a grant price of CNY 3.05 per share on July 11, 2025[18]. - The company plans to implement a stock incentive plan as approved in the shareholder meeting held on May 30, 2025[18]. Miscellaneous - The company's long-term equity investments decreased from CNY 214.46 million to CNY 166.12 million during the reporting period[21]. - The company’s third-quarter financial report was not audited[29].